pioglitazone has been researched along with Bipolar Disorder in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 9.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| "This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome." | 9.20 | Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Arbabi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Salimi, S; Sorayani, M; Zeinoddini, A, 2015) |
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 5.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| "This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome." | 5.20 | Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Arbabi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Salimi, S; Sorayani, M; Zeinoddini, A, 2015) |
| "Patients (n = 34) with bipolar disorder (I, II, or not otherwise specified) and metabolic syndrome/insulin resistance who were currently depressed (Quick Inventory of Depressive Symptoms [QIDS] total score ≥11) despite an adequate trial of a mood stabilizer received open-label, adjunctive treatment with the PPAR-γ agonist pioglitazone (15-30 mg/day) for 8 weeks." | 5.19 | PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. ( Calabrese, JR; Conroy, C; Ganocy, SJ; Gao, K; Ismail-Beigi, F; Kemp, DE; Schinagle, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aftab, A | 1 |
| Kemp, DE | 2 |
| Ganocy, SJ | 2 |
| Schinagle, M | 2 |
| Conroy, C | 2 |
| Brownrigg, B | 1 |
| D'Arcangelo, N | 1 |
| Goto, T | 1 |
| Woods, N | 1 |
| Serrano, MB | 1 |
| Han, H | 1 |
| Calabrese, JR | 2 |
| Gao, K | 2 |
| Ismail-Beigi, F | 1 |
| Zeinoddini, A | 1 |
| Sorayani, M | 1 |
| Hassanzadeh, E | 1 |
| Arbabi, M | 1 |
| Farokhnia, M | 1 |
| Salimi, S | 1 |
| Ghaleiha, A | 1 |
| Akhondzadeh, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression[NCT01717040] | Phase 4 | 37 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to The study ended early due to budgetary issues) | ||
| Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance[NCT00835120] | Phase 4 | 34 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipolar I Depression: An Open-Label Study[NCT04569448] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-05-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) is designed to assess the severity of depressive symptoms. Total scores can range from 0 to 84 with higher scores indicating a higher severity of depressive symptoms (NCT01717040)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 31.4 |
| Placebo | 24.3 |
"The CGI-BP asks the clinician one question: Considering your total clinical experience with this particular population, how mentally ill is the patient at this time? which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients." (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -1.9 |
The QIDS-SR16 is a 16-item, self report assessment. Total scores can range from 0 to 27, with higher scores indicating a worse outcome (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -7.1 |
Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) score change from baseline to study endpoint. IDS-C30 total scores can range from 0 to 84, with higher scores indicating a worse outcome (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -16.5 |
A participant is considered in remission if their total score on the MADRS is > 7, their total score on the QIDS-SR16 > 6 and/or their total score on the IDS-CR is > 12 at Week 8. (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 8 |
A participant is considered to have responded if their total score on either the MADRS or QIDS-SR16 decreases by at least 50% between their Week 0 visit and Week 8 visit. (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 13 |
3 trials available for pioglitazone and Bipolar Disorder
| Article | Year |
|---|---|
Double-blind, placebo-controlled trial of pioglitazone for bipolar depression.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depression; | 2019 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Double- | 2015 |